company
Breckenridge Pharmaceutical, Inc.
Jurisdiction: US
FDA Warning Letter timeline
V1 scope: FDA Warning Letters only. Additional public-record sources (SEC, CPSC, federal contracts) are on the V2 roadmap and are not surfaced here today.
- fda_recall · drug_recall2026-06-17Breckenridge Pharmaceutical, Inc. — Class II recall: Duloxetine Delayed-Release Capsules, USP, 60mg, packaged in a) 90 Capsules (NDC…
- fda_recall · drug_recall2026-06-17Breckenridge Pharmaceutical, Inc. — Class II recall: Duloxetine Delayed-Release Capsules, USP, 30mg, 1000 Capsule bottles, Rx only, M…
- fda_recall · drug_recall2026-05-13Breckenridge Pharmaceutical, Inc. — Class II recall: Duloxetine Delayed-Release Capsules USP, 60mg, Rx Only, 90-count bottle, Mfr. b…
Frequently asked questions
- How many FDA warning letters has Breckenridge Pharmaceutical, Inc. received?
- Argus HQ has not recorded an FDA warning letter for Breckenridge Pharmaceutical, Inc. in our current dataset.
- What FDA recalls has Breckenridge Pharmaceutical, Inc. issued?
- Argus HQ has recorded 3 FDA recalls tied to Breckenridge Pharmaceutical, Inc..
- Is Breckenridge Pharmaceutical, Inc. FDA compliant?
- Argus HQ is not a compliance rating service. As of this page's last update, our dataset shows 0 warning letters, 3 recalls, and 0 approval records for Breckenridge Pharmaceutical, Inc.. Review the linked FDA source records directly before drawing a compliance conclusion.
Informational only. FDA Warning Letters are public records (17 USC §105). Summaries are AI-assisted and may contain errors; always verify against the original FDA letter before acting. Not legal, financial, or regulatory advice.

